| Trial | Title | Study Record Detail | Phase | Sponsor/Collaborator |
|---|---|---|---|---|
| A Study of MLN0264 in Patients With Pancreatic Cancer | NCT02202785 | Phase II | Takeda / Millennium Pharmaceuticals, Inc. | |
| A Study of MLN0264 in Patients With Cancer of the Stomach or Gastroesophageal Junction | NCT02202759 | Phase II | Takeda / Millennium Pharmaceuticals, Inc. | |
| Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C | NCT01577758 | Phase I | Takeda / Millennium Pharmaceuticals, Inc. |
Indusatumab vedotin is also known as MLN-0264, 5F9vcMMAE, MLN-0264 and MLN0264
Last Editorial Review: July 30, 2016
